CureVac - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeCureVac
CureVac logo

CureVac

0 followers

CVAC

Performance

About CureVac

CureVac is a biotechnology company that specializes in messenger RNA (mRNA) therapeutics and vaccines, focusing on cancer immunotherapy and other serious diseases. The company has been integrated into the BioNTech Group, a global leader in next-generation immunotherapy. Through collaboration with BioNTech, CureVac contributes expertise in nucleic acid-based therapies and translational research to advance cancer and infectious disease treatments. The organization operates within the biotechnology sector with a global focus on developing novel therapeutics leveraging mRNA technology.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Alexander Zehnder, Dr.

Chief Executive Officer (CEO)

Axel Sven Malkomes

Chief Financial Officer (CFO)

Malte Greune, Dr.

Chief Operating Officer (COO)

Myriam Mendila, Dr.

Chief Scientific Officer (CSO) – Head R&D

Thaminda Ramanayake

Chief Business Officer (CBO)

Key Facts

HQ Location

Tübingen, Germany

Founded

2000

Employees

501-1K

Status

Public

Website

https://curevac.com